CORCEPT THERAPEUTICS INC Payments to Acquire Marketable Securities
CORCEPT THERAPEUTICS INC (CORT) reported Payments to Acquire Marketable Securities of $141.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC payments to acquire marketable securities for the quarter ending 2026-06-30 was $88.95M, a 282.21% increase year-over-year.
- CORCEPT THERAPEUTICS INC payments to acquire marketable securities for the quarter ending 2026-03-31 was $52.33M, a 54.55% decline year-over-year.
- CORCEPT THERAPEUTICS INC payments to acquire marketable securities for the quarter ending 2025-12-31 was $143.83M, a 0.51% decline year-over-year.
- CORCEPT THERAPEUTICS INC payments to acquire marketable securities for the quarter ending 2025-09-30 was $37.35M, a 83.26% decline year-over-year.
- CORCEPT THERAPEUTICS INC payments to acquire marketable securities for fiscal 2025 was $319.61M, a 45.67% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC payments to acquire marketable securities for fiscal 2024 was $588.31M, a 78.95% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC payments to acquire marketable securities for fiscal 2023 was $328.75M, a 7.41% decline from fiscal 2022.
- CORCEPT THERAPEUTICS INC payments to acquire marketable securities for fiscal 2022 was $355.07M, a 13.51% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 9 month as first filed | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $88.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $141.28M 10-Q · filed 2026-07-29 | $285.12M derived: sum of 3 quarters · filed 2026-07-29 | $322.47M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2026-03-31 | $52.33M 10-Q · filed 2026-04-30 | $196.16M derived: sum of 2 quarters · filed 2026-04-30 | $233.52M derived: sum of 3 quarters · filed 2026-04-30 | $256.79M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-12-31 | $143.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $181.19M derived: sum of 2 quarters · filed 2026-02-24 | $204.46M derived: sum of 3 quarters · filed 2026-07-29 | $319.61M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $37.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $60.63M derived: sum of 2 quarters · filed 2026-07-29 | $175.77M 10-Q · filed 2025-11-04 | $320.35M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-06-30 | $23.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $138.42M 10-Q · filed 2026-07-29 | $282.99M derived: sum of 3 quarters · filed 2026-07-29 | $506.13M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-03-31 | $115.14M 10-Q · filed 2026-04-30 | $259.72M derived: sum of 2 quarters · filed 2026-04-30 | $482.85M derived: sum of 3 quarters · filed 2026-04-30 | $625.58M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-12-31 | $144.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $367.71M derived: sum of 2 quarters · filed 2026-02-24 | $510.43M derived: sum of 3 quarters · filed 2026-02-24 | $588.31M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $223.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $365.86M derived: sum of 2 quarters · filed 2025-11-04 | $443.74M 10-Q · filed 2025-11-04 | $473.64M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $142.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $220.60M 10-Q · filed 2025-07-31 | $250.51M derived: sum of 3 quarters · filed 2026-02-24 | $460.54M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $77.88M 10-Q · filed 2025-05-05 | $107.78M derived: sum of 2 quarters · filed 2026-02-24 | $317.81M derived: sum of 3 quarters · filed 2026-02-24 | $406.62M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $29.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $239.93M derived: sum of 2 quarters · filed 2026-02-24 | $328.75M derived: sum of 3 quarters · filed 2026-02-24 | $328.75M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $210.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $298.85M derived: sum of 2 quarters · filed 2024-10-30 | $298.85M 10-Q · filed 2024-10-30 | $395.49M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $88.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-29 | $88.81M 10-Q · filed 2024-07-29 | $185.46M derived: sum of 3 quarters · filed 2025-02-26 | $264.31M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-01 | $96.64M derived: sum of 2 quarters · filed 2025-02-26 | $175.50M derived: sum of 3 quarters · filed 2025-02-26 | $262.45M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $96.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $175.50M derived: sum of 2 quarters · filed 2025-02-26 | $262.45M derived: sum of 3 quarters · filed 2025-02-26 | $355.07M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $78.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $165.81M derived: sum of 2 quarters · filed 2023-11-01 | $258.42M 10-Q · filed 2023-11-01 | $258.42M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2022-06-30 | $86.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $179.57M 10-Q · filed 2023-08-02 | $179.57M derived: sum of 3 quarters · filed 2024-02-15 | $269.11M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2022-03-31 | $92.61M 10-Q · filed 2023-05-03 | $92.61M derived: sum of 2 quarters · filed 2024-02-15 | $182.15M derived: sum of 3 quarters · filed 2024-02-15 | $278.03M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $89.54M derived: sum of 2 quarters · filed 2024-02-15 | $185.42M derived: sum of 3 quarters · filed 2024-02-15 | $312.81M 10-K · filed 2024-02-15 | ||
| 2021-09-30 | $89.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $185.42M derived: sum of 2 quarters · filed 2022-11-03 | $312.81M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $95.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $223.27M 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | $127.39M 10-Q · filed 2022-05-05 | |||||
| 2020-09-30 | $103.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $274.63M derived: sum of 2 quarters · filed 2021-11-03 | $323.09M 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $170.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $219.31M 10-Q · filed 2021-07-29 | ||||
| 2020-03-31 | $48.47M 10-Q · filed 2021-05-06 | |||||
| 2019-09-30 | $92.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | $152.40M derived: sum of 2 quarters · filed 2020-11-03 | $223.33M 10-Q · filed 2020-11-03 | |||
| 2019-06-30 | $60.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $131.00M 10-Q · filed 2020-08-04 | ||||
| 2019-03-31 | $70.94M 10-Q · filed 2020-05-04 | |||||
| 2018-09-30 | $81.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $126.46M derived: sum of 2 quarters · filed 2019-11-07 | $177.32M 10-Q · filed 2019-11-07 | $192.27M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $44.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $95.66M 10-Q · filed 2019-08-01 | $110.61M derived: sum of 3 quarters · filed 2019-08-01 | $132.85M derived: sum of 4 quarters · filed 2019-08-01 | ||
| 2018-03-31 | $50.87M 10-Q · filed 2019-05-09 | $65.81M derived: sum of 2 quarters · filed 2019-05-09 | $88.05M derived: sum of 3 quarters · filed 2019-05-09 | $104.60M derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $14.95M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $37.18M derived: sum of 2 quarters · filed 2018-11-02 | $53.73M derived: sum of 3 quarters · filed 2018-11-02 | $73.04M 10-K · filed 2018-02-28 | ||
| 2017-09-30 | $22.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $38.79M derived: sum of 2 quarters · filed 2018-11-02 | $58.09M 10-Q · filed 2018-11-02 | $45.62M 10-Q · filed 2017-11-03 | $58.09M derived: sum of 4 quarters · filed 2018-11-02 | |
| 2017-06-30 | $16.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $35.85M 10-Q · filed 2018-08-09 | $34.05M 10-Q · filed 2017-08-02 | $35.85M derived: sum of 3 quarters · filed 2018-08-09 | $35.85M derived: sum of 4 quarters · filed 2018-08-09 | |
| 2017-03-31 | $19.30M 10-Q · filed 2018-05-09 | $19.30M derived: sum of 2 quarters · filed 2018-05-09 | $19.30M derived: sum of 3 quarters · filed 2018-05-09 | $19.30M derived: sum of 4 quarters · filed 2018-05-09 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $0.00 derived: sum of 2 quarters · filed 2018-02-28 | $0.00 derived: sum of 3 quarters · filed 2018-02-28 | $0.00 10-K · filed 2018-02-28 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $0.00 derived: sum of 2 quarters · filed 2017-11-03 | $0.00 10-Q · filed 2017-11-03 | |||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $0.00 10-Q · filed 2017-08-02 | ||||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-02 | |||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |